International Journal of Clinical Pharmacy最新文献

{"title":"Letter to the Editor regarding \"Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample\".","authors":"Kirk E Evoy, Oliver Grundmann, Cassidy R LoParco, Matthew E Rossheim, Jordan R Covvey","doi":"10.1007/s11096-026-02227-8","DOIUrl":"https://doi.org/10.1007/s11096-026-02227-8","url":null,"abstract":"","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion of patients admitted to rural and remote hospitals that experience a 30-day medication-related readmission: a retrospective cohort study.","authors":"Kingston Yeung, Gi Kon Nam, Klaudia Englezos, Aagam Bordia, Stephen Carter, Rebekah Moles, Hana Amer, Manya Angley, Charley Budgeon, Brett Chambers, Jenny Chen, Deirdre Criddle, Rohan A Elliott, Tara Emadi, Cristen Fleming, Deborah Hawthorne, Linda Krogh, Anna Packer, Simon Poon, Frank M Sanfilippo, Paul Yates, Jerry Yik, Jonathan Penm","doi":"10.1007/s11096-026-02228-7","DOIUrl":"https://doi.org/10.1007/s11096-026-02228-7","url":null,"abstract":"<p><strong>Introduction: </strong>Medication-related readmissions are a significant and preventable cause of patient harm. Patients living in rural and remote areas may face inequitable access to healthcare and fragmented continuity of care, increasing their vulnerability to medication-related harm. Despite this, the burden and drivers of medication-related readmissions in these settings remain poorly understood. Determining the current burden and identifying factors associated with medication-related readmissions is essential to inform targeted strategies to improve medication safety.</p><p><strong>Aim: </strong>To determine the proportion of adult patients with a medication-related readmission within 30 days of discharge from rural and remote hospitals, and to identify factors potentially associated with these readmissions.</p><p><strong>Method: </strong>A retrospective cohort study was conducted using medical records of adults admitted to rural and remote hospitals in New South Wales, Australia, between June 1, 2022 and August 31, 2023. Readmissions within 30 days were assessed for medication-related causes using the AT-HARM10, a validated 10-item tool based on admission notes, medication lists, inpatient pathology results, and discharge summaries. Patient demographics, comorbidities and admission details were extracted. Comorbidity burden was calculated using the Charlson Comorbidity Index (CCI). Medication lists were based on medications charted 12 h before discharge. Univariable logistic regression was performed to explore factors associated with 30-day medication-related readmissions, with results reported as unadjusted odds ratios (uOR).</p><p><strong>Results: </strong>Of the 2220 patients admitted during the study period, 6% (n = 133) experienced a 30-day readmission, of which 22.5% (n = 30) were medication-related. Overall, 1.4% of all admitted patients experienced a 30-day medication-related readmission. Older age (uOR 1.04; 95% CI 1.01-1.07), higher CCI (uOR 1.22; 95% CI 1.04-1.44), a greater number of regular medications (uOR 1.07 per additional medication; 95% CI 1.01-1.14), and insulin use (uOR 2.80; 95% CI 1.06-7.42) were associated with medication-related readmission.</p><p><strong>Conclusion: </strong>In rural and remote hospitals, a small but clinically important proportion of patients experienced a medication-related readmission within 30 days of discharge. Unadjusted analysis identified that older age, multimorbidity, polypharmacy and insulin use were associated with increased risk. Larger studies are needed to validate these findings and evaluate strategies to reduce medication-related harm in rural and remote populations.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment recommendations for recurrent vulvovaginal candidiasis across complementary and conventional disciplines: a national survey of Australian healthcare professionals.","authors":"Rommy Everingham-Gordon, Elizabeth Steels, Cathy J Watson, Kathryn J Steadman","doi":"10.1007/s11096-026-02165-5","DOIUrl":"10.1007/s11096-026-02165-5","url":null,"abstract":"<p><strong>Introduction: </strong>Management of recurrent vulvovaginal candidiasis remains challenging. It is treated by healthcare professionals across disciplines including general practice, pharmacy, and complementary medicine. Conventional antifungal regimens supported by formal treatment guidelines are the standard of care. No standardised guidance exists for complementary medicine, and the treatments used in contemporary practice remain largely undocumented.</p><p><strong>Aim: </strong>To identify treatments recommended for recurrent vulvovaginal candidiasis across healthcare disciplines and the sources used to inform clinical decisions.</p><p><strong>Method: </strong>A national cross-sectional, open, anonymous, self-administered online survey of Australian healthcare professionals from conventional and complementary medicine disciplines was conducted between November 2022 and September 2023 using a 19-item questionnaire. The questionnaire captured treatment recommendations for recurrent or persistent Candida-related vulvovaginal symptoms, including conventional and complementary medicines, over-the-counter products, and lifestyle strategies such as dietary and hygiene advice, and information sources used in diagnosis and management.</p><p><strong>Results: </strong>A total of 223 healthcare professionals from 13 disciplines met the inclusion criteria, comprising 68 conventional medicine and 155 complementary medicine practitioners. Overall, 122 different treatments were identified, including 69 distinct herbal medicines, reflecting substantial variation in clinical recommendations across disciplines. Conventional medicines were recommended by 43.9% of respondents, herbal medicines by 65.0%, and nutrient-based interventions by 86.1%. Oral fluconazole and intravaginal clotrimazole were the most frequently recommended conventional agents. Probiotics, administered either orally or intravaginally, were cited across professional groups. Frequently recommended herbal medicines included Allium sativum (garlic), Handroanthus impetiginosus (pau d'arco), and Pseudowintera colorata (horopito). Common lifestyle strategies included reducing dietary sugar, alcohol moderation, avoiding synthetic underwear, and modifying post-toileting hygiene practices. Information sources also differed by discipline, with conventional medicine practitioners more often consulting the Therapeutic Guidelines (eTG) and complementary medicine practitioners more commonly consulting peer-reviewed journal articles.</p><p><strong>Conclusion: </strong>Practitioner-reported recurrent vulvovaginal candidiasis management included a broad range of treatment strategies across healthcare disciplines. The heterogeneity of recommendations, together with overlap across disciplines, supports further evaluation of selected treatments and evidence-informed cross-disciplinary guidance to support safer, more coordinated care.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1926-1936"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to clinical data for direct oral anticoagulant prescriptions in community pharmacy and implications for medication optimisation: a mixed-methods study.","authors":"Jacqueline G van Paassen, Vera H M Deneer, Thomas G H Kempen, Marcel L Bouvy","doi":"10.1007/s11096-026-02159-3","DOIUrl":"10.1007/s11096-026-02159-3","url":null,"abstract":"<p><strong>Introduction: </strong>Inappropriate direct oral anticoagulant (DOAC) prescribing is a frequent cause of harm to patients. Pharmacists could play an important role in optimising prescribing, but they need access to relevant clinical data to do so. Little is known about community pharmacists' access to clinical data to assess the appropriateness of DOAC prescriptions.</p><p><strong>Aim: </strong>To investigate the availability of relevant clinical data for DOAC prescriptions and whether additionally requesting such data supports community pharmacists in assessing and optimising DOAC prescriptions. This study also explored behavioural factors influencing pharmacists' decisions to request additional clinical data.</p><p><strong>Method: </strong>In this mixed-methods study, 166 community pharmacies were approached to collect quantitative data. This included the prevalence of missing clinical data, pharmacists' requests for missing data including reasons for requesting these data, and prescription adjustments made by the pharmacist. Missing clinical data was defined as absence of patient information on the DOAC prescription to assess its appropriateness: treatment indication, renal function, body weight, treatment duration, or concomitant use of antithrombotics. A random sample of 10 participating pharmacies was approached for semi-structured interviews on perceptions whether to request missing clinical data. Quantitative data were analysed descriptively. Interviews were thematically analysed using the Capability, Opportunity, Motivation, Behaviour (COM-B) framework to understand behaviour. Quantitative and qualitative data were triangulated through discussion of the findings.</p><p><strong>Results: </strong>We collected quantitative data of 583 DOAC prescriptions in 92 pharmacies and interviewed 11 pharmacists from 10 approached pharmacies. On 92.8% (n = 541) of DOAC prescriptions clinical data were missing. Additional clinical data (particularly, treatment indication and renal function) were requested in 51.9% (n = 281), mainly for dose evaluation (39.6% (n = 231)), leading to 5.0% (n = 14) adjustments of these prescriptions. Pharmacists applied clinical reasoning to determine the need for additional data, with providing optimal patient care as their primary motivation. The main opportunity was collaboration with other healthcare professionals.</p><p><strong>Conclusion: </strong>Using their clinical reasoning competence, pharmacists frequently requested missing clinical data, particularly treatment indication and renal function, to verify DOAC prescriptions and to ensure optimal patient care. Clinical data sharing could be optimised by streamlined collaboration between healthcare professionals.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1871-1883"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral anticoagulant switching in patients with atrial fibrillation: a long-term cohort study using population-level administrative data.","authors":"Adenike R Adelakun, Ricky D Turgeon, Mary A De Vera, Kim McGrail, Abdollah Safari, Peter S Loewen","doi":"10.1007/s11096-026-02163-7","DOIUrl":"10.1007/s11096-026-02163-7","url":null,"abstract":"<p><strong>Introduction: </strong>Patient characteristics and clinical factors could necessitate switching between oral anticoagulants (OACs) for stroke prevention in atrial fibrillation (AF), a phenomenon whose causes and consequences are understudied.</p><p><strong>Aim: </strong>Our objectives were to describe longitudinal patterns of OAC switching in patients with AF and to identify factors associated with switching.</p><p><strong>Method: </strong>A cohort of adult AF patients were identified in Canadian administrative health data from 1996 to 2019. An OAC switch was defined as a change from one OAC to a different OAC with a gap of ≤ 30 days between prescriptions. Switch events were characterized, and factors associated with switches were analyzed using Cox regression.</p><p><strong>Results: </strong>The cohort comprised 30,264 patients. One quarter experienced an OAC switch and 22% of those had ≥ 2 switch events. Vitamin K antagonist (VKA) to direct-acting oral anticoagulant (DOAC) was the most frequent switch type (63%). Switching to a previous OAC occurred commonly (19%-26%). A quarter of patients who switched from warfarin to a DOAC switched back to warfarin. Hospitalizations for AF, acute renal failure, vascular disease, gastrointestinal bleeding, and/or stroke ≤ 90 days before a switch had the highest hazards for VKA to DOAC switch. Hospitalizations for AF, stroke, major bleeding, vascular disease, and/or heart failure (HF) ≤ 90 days before a switch had the highest hazards for DOAC to VKA switch. Hospitalizations for AF, major bleeding, acute renal failure, vascular disease, stroke, and/or HF ≤ 90 days before a switch had the highest hazards for switch between DOACs.</p><p><strong>Conclusion: </strong>OAC switching is frequently required in AF patients, with many needing to return to a previously used agent. Switches may reflect an intention to maximize stroke prevention effectiveness and safety, but further research is needed to assess the risks and benefits of OAC switching.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1904-1914"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research trends and emerging topics in antifungal therapeutic drug monitoring: a bibliometric analysis with implications for clinical pharmacy practice.","authors":"Li-Chao-Yue Sun, Jian-Chun Li, Wen-Shu Li, Zhao Ren, Yi-Xin Yang, Wei Liu, Suo-Di Zhai, Shuo Liang, Zhi-Heng Yu","doi":"10.1007/s11096-026-02175-3","DOIUrl":"10.1007/s11096-026-02175-3","url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic drug monitoring (TDM) plays an important role in optimizing antifungal pharmacotherapy because of the substantial pharmacokinetic variability and narrow therapeutic window of many antifungal agents. However, the global research landscape and emerging trends in antifungal TDM have not been systematically evaluated.</p><p><strong>Aim: </strong>This study aimed to analyze global research trends, collaboration networks, and emerging research hotspots in antifungal TDM using bibliometric analyses.</p><p><strong>Method: </strong>Relevant publications published between January 2014 and November 14, 2024, were retrieved from the Web of Science Core Collection. Bibliometric analyses were performed using CiteSpace and VOSviewer to evaluate publication trends, countries, institutions, authors, journals, and keyword co-occurrence.</p><p><strong>Results: </strong>A total of 569 publications from 34 countries were included in this review. The United States, China, and Germany were the leading contributors, and the annual publication output increased steadily during the study period. The French National Institute of Health and Medical Research was the most productive institution. The most influential journals were Antimicrobial Agents and Chemotherapy and Clinical Microbiology and Infection. Keyword analysis identified voriconazole TDM, drug-drug interactions, caspofungin, invasive aspergillosis, extracorporeal membrane oxygenation, and immunocompromised pediatric populations as major research hotspots. Machine learning-assisted pharmacokinetic modeling has recently emerged as a research focus.</p><p><strong>Conclusion: </strong>Although research on antifungal TDM is increasing globally, high-quality clinical evidence remains limited. Future research should prioritize multicenter clinical studies, optimization of TDM implementation in special populations, and integration of model-informed precision dosing approaches to support individualized antifungal therapy and clinical pharmacy practice.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1787-1799"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and reliability testing of BRANT-MERQS-2A: A quality assessment tool for medication review type 2a reports.","authors":"Eline Tobback, Annouk Peeters, Nabileh Basir, Emilie Van Haver, Juno Quayhackx, Maja Brumer, Ronja Woltersdorf, Guido R Y De Meyer, Hans De Loof","doi":"10.1007/s11096-026-02174-4","DOIUrl":"10.1007/s11096-026-02174-4","url":null,"abstract":"<p><strong>Introduction: </strong>Medication reviews (MRs) are increasingly implemented to optimize medication use and address drug-related problems in patients with complex pharmacotherapy, with medication review type 2a (MR2a) representing an intermediate format involving a pharmacist-led structured assessment with patient interview, based on clinical and medication data, without direct prescriber interaction. Despite their widespread implementation, systematic and operational approaches to evaluate the quality of MRs remain limited. In Belgium, Medication Review type 2a (MR2a) has been implemented in routine practice of community pharmacies since 2023, yet no validated instruments exist to evaluate the quality of written MR2a reports.</p><p><strong>Aim: </strong>This study aimed to adapt the existing BRANT-MERQS framework for the quality evaluation of MR2a reports and to assess the usability, reproducibility and reliability of the resulting tool (BRANT-MERQS-2A).</p><p><strong>Method: </strong>Relevant criteria were selected from the original BRANT-MERQS and expanded with criterion-specific instructions to form the BRANT-MERQS-2A. Initial testing involved two student assessors independently evaluating 98 MR2a reports, with interrater agreement (IRA) assessed using weighted Cohen's Kappa. In a subsequent extended testing phase, the same reports were assessed by 61 final-year pharmacy students, with three randomly selected students evaluating each MR2A report. Interrater reliability was evaluated using the Intraclass Correlation Coefficient (ICC) and Gwet's AC1. Assessment duration was recorded to evaluate feasibility.</p><p><strong>Results: </strong>Initial testing demonstrated strong IRA between the two student assessors. In the extended student cohort, agreement at the criterion level ranged from poor to moderate, with an overall ICC of 0.62, indicating moderate reliability. Criteria differed in discriminatory capacity, with some showing high absolute agreement but limited variability. Assessment time decreased over successive rounds, reflecting a learning effect and improved efficiency.</p><p><strong>Conclusion: </strong>The BRANT-MERQS-2A provides a feasible and structured approach for assessing the quality of MR2a reports. While variability at criterion level reflects the inherent complexity of MR2a, the tool demonstrates potential for self-and peer-assessment and offers a valuable foundation for further refinement and integration into routine quality monitoring.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"1967-1978"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical pharmacy in Syria at a crossroads: challenges, opportunities, and pathways for post-conflict reform.","authors":"Tarik Al-Diery, Ammar Al-Abdullah, Amani Zidan, Marah Mazen Jafar, Ayman Hameed, Salah Al-Deen Al-Safadi, Abdo Mahli","doi":"10.1007/s11096-026-02168-2","DOIUrl":"10.1007/s11096-026-02168-2","url":null,"abstract":"<p><p>Following more than a decade of conflict and humanitarian crises, Syria's health and higher education systems have experienced profound disruption, with lasting consequences for the pharmacy profession. Clinical pharmacy, in particular, remains underdeveloped despite its well-established potential to improve patient outcomes and support an overstretched healthcare system. This commentary critically examines the current landscape of clinical pharmacy education, training, and practice in Syria, highlighting the structural, regulatory, and cultural barriers that have constrained its advancement. Drawing on available evidence and the authors' professional expertise in clinical pharmacy education and workforce development, the commentary examines the persistent theory-practice gap across undergraduate and postgraduate training and identifies key areas for reform. Building on this analysis, the commentary proposes context-sensitive future directions to strengthen clinical pharmacy in Syria. These include reforming competency-based curricula at the undergraduate and postgraduate levels, establishing hospital pharmacy residency programs accredited by pharmacy specific hospital organisations, investing in clinical pharmacy units within governmental hospitals, developing and supporting pharmacy preceptors and mentors, and fostering a culture of clinical and practice-based research. The role of professional pharmacy bodies and the Syrian diaspora in capacity building and mentorship is also emphasised as a bridge to achieving such desired outcomes. Ultimately, transforming clinical pharmacy in Syria will require coordinated leadership and sustained commitment from both the Ministry of Health and the Ministry of Higher Education. If aligned reform is pursued, clinical pharmacy can evolve from a marginalised practice into an essential pillar of Syria's post-conflict health system, contributing to improved patient outcomes and long-term system resilience.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2169-2178"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?","authors":"Edel Burton, Kate E Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J Sahm, Séamus O'Reilly","doi":"10.1007/s11096-026-02192-2","DOIUrl":"10.1007/s11096-026-02192-2","url":null,"abstract":"<p><p>The introduction of biologics marked a paradigm shift in the treatment of numerous life threatening and life limiting diseases such as cancer. Addressing cost effectiveness in medical oncology is necessary as cancer cases are expected to increase globally by nearly 60% in the next decade which will place an increasing demand on effective drug options. Biologic drugs carry a significant financial burden which could be alleviated with the increased use of biosimilars without compromising on quality, safety, or efficacy. Global spending on cancer drugs is expected to rise from $223 billion in 2023 to $409 billion in 2028 which is largely driven by the authorisation of novel biologic drugs. The cost of cancer drugs in Irish hospitals surged from €4.7 million in 2013 to €151 million in 2022-a gain exceeding 3,100%. The Irish Health Service Executive reported a low uptake of biosimilars with usage varying widely between hospitals. Barriers to the use of biosimilars included resistance to substitution at the community pharmacy level, and introduction of subcutaneous biologics that extend patent protection. In conclusion there remains significant potential to improve biosimilar adoption rates in Ireland which would allow both increased patient access and treatment equity. Thus, this commentary explores the use of biosimilars to address this financial burden in medical oncology and increase access to biologic cancer drugs.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2179-2186"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital pharmacists' perceptions, needs, barriers, and facilitators of pharmacy practice research in China: a qualitative study.","authors":"Chu Zhang, Yanping Wu, Xin Li","doi":"10.1007/s11096-026-02197-x","DOIUrl":"10.1007/s11096-026-02197-x","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacy practice research has received increasing international attention but remains in its early stages in China. Understanding pharmacists' engagement in such research is essential for advancing pharmaceutical care and strengthening evidence-based practice.</p><p><strong>Aim: </strong>This study aimed to explore hospital pharmacists' perceptions of pharmacy practice research and identify the factors influencing their engagement in such research.</p><p><strong>Method: </strong>This qualitative study employed semi-structured interviews with 21 pharmacists from Grade A tertiary hospitals across 14 provinces and municipalities in China. Participants were purposively sampled to ensure variation in their professional roles, experience, and geographic region. The interviews were conducted online, audio recorded, and transcribed verbatim. Data were analyzed using thematic analysis informed by the COM-B framework and were managed using NVivo 12. Coding was performed independently by two researchers, and discrepancies were resolved through discussion to enhance the analytical rigor.</p><p><strong>Results: </strong>Three overarching themes and 18 subthemes were identified. Most participants recognized the importance of pharmacy practice research and expressed a strong willingness to engage, particularly when research activities were closely aligned with their clinical practices. The key motivations included professional fulfillment, career advancement, and personal research interests. The identified research needs focused on optimizing pharmaceutical service content and models and strengthening information system support to facilitate data access and decision-making. Institutional support, a positive research culture, and interdisciplinary collaboration were important facilitators of engagement. However, major barriers include insufficient time and staffing, limited research resources, and inadequate research competence.</p><p><strong>Conclusion: </strong>Hospital pharmacists in China generally recognize the value of pharmacy practice research; however, their engagement is shaped by capability-, opportunity-, and motivation-related factors, including research competence, organizational support, resource availability, and interdisciplinary collaboration. Strengthening research training, institutional support, and collaborative research environments may enhance pharmacists' engagement in pharmacy practice.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":"2117-2127"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}